Guided Therapeutics (GTHP) Return on Sales (2016 - 2025)
Guided Therapeutics (GTHP) has disclosed Return on Sales for 16 consecutive years, with 2.06% as the latest value for Q4 2025.
- Quarterly Return on Sales rose 64994.0% to 2.06% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 4.17% through Dec 2025, up 34112.0% year-over-year, with the annual reading at 4.17% for FY2025, 34112.0% up from the prior year.
- Return on Sales hit 2.06% in Q4 2025 for Guided Therapeutics, up from 12.37% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 3.58% in Q3 2021 to a low of 2442.0% in Q1 2025.
- Historically, Return on Sales has averaged 250.04% across 5 years, with a median of 56.91% in 2024.
- Biggest YoY gain for Return on Sales was 64994bps in 2025; the steepest drop was -237500bps in 2025.
- Year by year, Return on Sales stood at 7.4% in 2021, then crashed by -4414bps to 334.0% in 2022, then skyrocketed by 96bps to 12.06% in 2023, then tumbled by -5305bps to 652.0% in 2024, then soared by 100bps to 2.06% in 2025.
- Business Quant data shows Return on Sales for GTHP at 2.06% in Q4 2025, 12.37% in Q3 2025, and 6.93% in Q2 2025.